We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+29.04%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$514M
AUM Growth
-$44.2M
Cap. Flow
-$142M
Cap. Flow %
-27.71%
Top 10 Hldgs %
56.71%
Holding
50
New
12
Increased
6
Reduced
15
Closed
13

Top Buys

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$16.4M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$11.6M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$9.99M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.58M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$8.38M

Top Sells

Rank Stock Value
1
ADMS
Adamas Pharmaceuticals
ADMS
+$35.9M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$29M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$24.8M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$23.6M
5
ZGNX
Zogenix, Inc.
ZGNX
+$19.3M

Sector Composition

Rank Sector Weight
1 Healthcare 68.75%
2 Technology 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
1
DELISTED
Zogenix, Inc.
ZGNX
$35.8M 6.96%
1,021,331
-1,419,628
-58% -$19.3M
UTHR icon
2
CALL
United Therapeutics
UTHR
$25.8B
$35.2M 6.84%
+300,000
New +$38.3M
ARNA
3
DELISTED
Arena Pharmaceuticals Inc
ARNA
$34.6M 6.74%
1,357,800
-1,082,130
-44% -$24.8M
CNCE
4
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$29.6M 5.76%
2,006,211
+6,211
+0.3% +$90.1K
ALNY icon
5
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
$29.4M 5.71%
+250,000
New +$21.3M
NBIX icon
6
Neurocrine Biosciences
NBIX
$16.8B
$29.1M 5.66%
475,000
-125,000
-21% -$6.6M
FOMX
7
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$26.5M 5.16%
4,781,708
– –
KURA icon
8
Kura Oncology
KURA
$800M
$26.2M 5.09%
+1,750,887
New +$16.4M
RIGL icon
9
Rigel Pharmaceuticals
RIGL
$681M
$23.1M 4.5%
910,569
– –
PTCT icon
10
PTC Therapeutics
PTCT
$5.64B
$22M 4.28%
1,100,000
-800,000
-42% -$15.7M
DBVT
11
DBV Technologies
DBVT
$799M
$19.1M 3.72%
45,089
-4,911
-10% -$2.1M
ZGNX
12
CALL
DELISTED
Zogenix, Inc.
ZGNX
$17.5M 3.41%
+500,000
New +$6.79M
GBT
13
DELISTED
Global Blood Therapeutics, Inc.
GBT
$17.4M 3.39%
560,498
+305,098
+119% +$8.58M
RNAC icon
14
Cartesian Therapeutics
RNAC
$229M
$16.5M 3.2%
30,062
-1,188
-4% -$632K
IOVA icon
15
Iovance Biotherapeutics
IOVA
$1.82B
$15.5M 3.02%
2,000,000
+1,830,986
+1,083% +$11.6M
RXDX
16
DELISTED
Ignyta, Inc.
RXDX
$15.3M 2.98%
1,241,752
-507,571
-29% -$5.23M
ZGNX
17
PUT
DELISTED
Zogenix, Inc.
ZGNX
$13.1M 2.56%
+375,000
New +$5.09M
AIMT
18
DELISTED
Aimmune Therapeutics
AIMT
$12.4M 2.41%
500,000
+64,598
+15% +$1.39M
SRPT icon
19
Sarepta Therapeutics
SRPT
$1.57B
$11.3M 2.21%
+250,000
New +$9.99M
SGYP
20
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$9.49M 1.85%
3,273,509
-3,950,000
-55% -$13.5M
PTCT icon
21
CALL
PTC Therapeutics
PTCT
$5.64B
$9.21M 1.79%
460,000
+200,000
+77% +$3.92M
VNDA icon
22
Vanda Pharmaceuticals
VNDA
$307M
$8.91M 1.73%
497,531
-1,734,707
-78% -$29M
BCRX icon
23
BioCryst Pharmaceuticals
BCRX
$2.28B
$8.58M 1.67%
+1,637,332
New +$8.38M
SAGE
24
DELISTED
Sage Therapeutics
SAGE
$6.82M 1.33%
109,500
-134,300
-55% -$10.5M
XLRN
25
DELISTED
Acceleron Pharma
XLRN
$6.34M 1.23%
170,000
-323,500
-66% -$11.2M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2017 Portfolio in Review

As of Q3 2017, Great Point Partners held 50 positions worth $514M, down 7.9% from $558M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Great Point Partners withdrew a net $142M in Q3 2017, closing 13 positions and reducing 15 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $23.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 79% a quarter earlier, followed by Technology.

Against the trend, Great Point Partners opened a new position in Kura Oncology worth $26.2M.

  • Great Point Partners's largest Q3 2017 buy was Kura Oncology: 1,750,887 shares worth $26.2M.
  • Great Point Partners added most to Iovance Biotherapeutics in Q3 2017, an estimated $11.6M increase.
  • Great Point Partners's biggest Q3 2017 reduction was Adamas Pharmaceuticals, cutting an estimated $35.9M.
  • Great Point Partners fully exited Alnylam Pharmaceuticals in Q3 2017, selling an estimated $23.6M.
  • Great Point Partners's ten largest holdings make up 57% of its $514M portfolio in Q3 2017.
  • Great Point Partners opened 12 new positions and closed 13 in Q3 2017.
  • Great Point Partners's portfolio value fell 7.9% quarter-over-quarter to $514M.

Based on Great Point Partners's 13F filing for Q3 2017, filed 14 Nov 2017.